EyePoint, Inc.
EYPT Nasdaq Laboratory Analytical Instruments Financials FY2015βFY2025
What EyePoint, Inc. does
No business description yet.
- Legal name
- EyePoint, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 5, 2026
- Accession Β· CIK
- 0001193125-26-093917
0001314102
Revenue and margins
EyePoint, Inc. had $31.4M of revenue in fiscal 2025, down 27.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$243M in fiscal 2025, β775.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
EyePoint, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 30.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably EyePoint, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $212M | $145M | $331M | $371M | $306M |
| Debt incl. finance leases | $36.7M | $40.5M | $0.0M | β | β |
| Debt / equity | 0.2x | 0.4x | 0.0x | β | β |
| Interest coverage | β10.1x | β31.2x | β60.2x | β10,418.1x | β7,376.8x |
| Current ratio | 10.0x | 5.0x | 5.5x | 7.8x | 8.9x |
| Quick ratio | 9.9x | 4.9x | 5.4x | 7.8x | 8.8x |
| Total assets | $263M | $180M | $355M | $418M | $364M |
| Total liabilities | $79.0M | $84.0M | $88.9M | $82.0M | $57.9M |
| Shareholders' equity | $184M | $96.4M | $266M | $337M | $306M |
| Net debt (β = net cash) | β$175M | β$104M | β$331M | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY15 | FY16 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 7 | β / 3 | 4 / 8 | 5 / 8 | 4 / 8 | 2 / 8 | 6 / 8 | 2 / 7 | 1 / 7 |
| Accruals ratio | β16.5% | 8.0% | β40.0% | β0.1% | β37.6% | β4.7% | β16.8% | β27.1% | β1.2% | 2.1% |
| Altman Z'' | β27.55 | β53.94 | β16.13 | β22.34 | β17.17 | β0.67 | β9.61 | 0.11 | 0.41 | β3.58 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY15 | FY16 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.6M | $7.5M | $3.0M | $20.4M | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Research and development | $14.4M | $14.9M | $16.2M | $15.4M | $17.4M | $28.5M | $49.6M | $64.7M | $133M | $221M |
| Operating income | β$21.8M | β$18.6M | β$26.3M | β$47.9M | β$37.3M | β$55.3M | β$99.6M | β$75.1M | β$146M | β$243M |
| Interest expense | $0.0M | $0.0M | $0.7M | $6.2M | $7.3M | $5.5M | $3.2M | $1.2M | $0.0M | $0.0M |
| Pretax income | β$21.7M | β$18.5M | β$53.2M | β$56.8M | β$45.4M | β$58.4M | β$102M | β$70.7M | β$131M | β$232M |
| Income tax | β$0.2M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.3M |
| Net income | β$21.5M | β$18.5M | β$53.2M | β$56.8M | β$45.4M | β$58.4M | β$102M | β$70.8M | β$131M | β$232M |
| Diluted EPS | β$0.68 | β$0.52 | β$1.15 | β$5.44 | β$3.54 | β$2.03 | β$2.74 | β$1.82 | β$2.32 | β$3.17 |
| Diluted shares | 0.03B | 0.04B | 0.05B | 0.01B | 0.01B | 0.03B | 0.04B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$16.3M | β$20.5M | β$21.9M | β$56.7M | β$14.4M | β$50.1M | β$65.0M | $1.9M | β$126M | β$240M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.2M | $0.4M | $0.2M | $2.2M | $3.5M | $4.1M | $3.3M |
| Free cash flow | β$16.4M | β$20.6M | β$22.0M | β$56.9M | β$14.8M | β$50.3M | β$67.2M | β$1.6M | β$130M | β$243M |
| Depreciation and amortization | $0.2M | $0.1M | $0.2M | $0.1M | $0.2M | $0.3M | $0.4M | $0.5M | $1.5M | $2.3M |
| Stock-based compensation | $2.2M | $2.5M | $2.7M | $4.6M | $5.5M | $7.4M | $14.2M | $12.1M | $36.7M | $27.9M |
| Acquisitions | $0.0M | $0.0M | $16.8M | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $29.0M | $16.9M | $45.3M | $22.2M | $44.9M | $212M | $145M | $331M | $371M | $306M |
| Total debt | β | $0.0M | $17.6M | $47.2M | $38.0M | $36.6M | $40.5M | $0.0M | β | β |
| Finance lease liabilities | β | β | β | $0.0M | $0.2M | $0.2M | $0.0M | β | β | β |
| Current assets | $30.0M | $17.7M | $47.6M | $41.7M | $63.1M | $238M | $173M | $345M | $383M | $329M |
| Current liabilities | $5.1M | $5.3M | $21.5M | $11.5M | $14.9M | $23.7M | $34.5M | $63.3M | $49.0M | $37.0M |
| Inventory | β | $0.0M | $0.3M | $2.1M | $5.3M | $3.6M | $2.9M | $3.9M | $2.3M | $1.8M |
| Property and equipment, net | $0.3M | $0.3M | $0.3M | $0.4M | $0.6M | $0.5M | $1.4M | $5.3M | $8.2M | $9.0M |
| Intangible assets | $1.1M | $0.4M | $30.1M | $27.7M | $25.2M | $22.7M | $0.0M | β | β | β |
| Total assets | $31.6M | $18.7M | $78.2M | $73.0M | $91.7M | $263M | $180M | $355M | $418M | $364M |
| Total liabilities | $10.7M | $5.3M | $40.5M | $64.6M | $73.2M | $79.0M | $84.0M | $88.9M | $82.0M | $57.9M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $20.9M | $13.3M | $37.6M | $8.3M | $18.5M | $184M | $96.4M | $266M | $337M | $306M |
| Margins | ||||||||||
| Operating margin | β1,344.1% | β246.4% | β887.3% | β235.0% | β108.3% | β149.6% | β240.6% | β163.1% | β337.1% | β776.0% |
| EBITDA margin | β1,334.7% | β245.2% | β881.7% | β234.3% | β107.7% | β148.8% | β239.7% | β162.1% | β333.5% | β768.6% |
| Net margin | β1,330.1% | β245.2% | β1,795.7% | β278.9% | β131.8% | β158.1% | β247.0% | β153.8% | β302.4% | β739.4% |
| FCF margin | β1,014.1% | β273.7% | β743.5% | β279.5% | β43.0% | β136.0% | β162.2% | β3.5% | β301.1% | β775.8% |
| Returns | ||||||||||
| Return on capital | β | β | β207.7% | β113.4% | β253.8% | β465.3% | β | β | β | β |
| Return on capital employed | β82.1% | β138.8% | β46.3% | β77.9% | β48.5% | β23.1% | β68.3% | β25.7% | β39.5% | β74.5% |
| Return on equity | β103.2% | β108.0% | β141.3% | β247.1% | β337.9% | β57.6% | β72.8% | β39.0% | β43.4% | β72.2% |
| Return on assets | β68.1% | β73.5% | β68.0% | β75.2% | β55.1% | β32.9% | β46.1% | β26.4% | β33.8% | β59.3% |
| Return on tangible equity | β108.9% | β142.5% | β708.6% | β | β | β36.1% | β106.1% | β26.6% | β38.9% | β75.8% |
| Growth | ||||||||||
| Revenue growth | β | 365.4% | β | 587.8% | 69.1% | 7.3% | 12.1% | 11.1% | β6.0% | β27.5% |
| Share count change | β | 11.8% | β | β77.4% | 23.1% | 124.0% | 29.8% | β99.9% | 44.7% | 30.2% |
| Financial health | ||||||||||
| Debt / equity | β | 0.0x | 0.5x | 5.7x | 2.0x | 0.2x | 0.4x | 0.0x | β | β |
| Interest coverage | β | β | β36.5x | β7.7x | β5.1x | β10.1x | β31.2x | β60.2x | β10,418.1x | β7,376.8x |
| Current ratio | 5.9x | 3.4x | 2.2x | 3.6x | 4.2x | 10.0x | 5.0x | 5.5x | 7.8x | 8.9x |
| Quick ratio | 5.9x | 3.4x | 2.2x | 3.4x | 3.9x | 9.9x | 4.9x | 5.4x | 7.8x | 8.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 7.0% | 1.9% | 3.6% | 1.0% | 1.1% | 0.4% | 5.2% | 7.6% | 9.4% | 10.5% |
| Stock comp / revenue | 133.5% | 32.6% | 91.3% | 22.4% | 16.1% | 20.2% | 34.2% | 26.2% | 84.9% | 88.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 1.0 | β | 4.0 | 5.0 | 4.0 | 2.0 | 6.0 | 2.0 | 1.0 |
| Altman Z'' | β27.6 | β53.9 | β16.1 | β22.3 | β17.2 | β0.7 | β9.6 | 0.1 | 0.4 | β3.6 |
| Accruals ratio | β16.5% | 8.0% | β40.0% | β0.1% | β37.6% | β4.7% | β16.8% | β27.1% | β1.2% | 2.1% |
Source: SEC EDGAR XBRL filings (CIK 0001314102). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.